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Abstract (word count: 199) 
Immunotherapy represents a promising area of therapy among neuro-oncology patients. However, 
early phase studies reveal unique challenges associated with assessment of radiological changes 
reflecting delayed responses or therapy-induced inflammation. Clinical benefit, including long-
term survival and tumor regression, can still occur following initial apparent progression or 
appearance of new lesions. Refinement of response assessment criteria for neuro-oncology 
patients undergoing immunotherapy is therefore warranted. A multinational and multidisciplinary 
panel of neuro-oncology immunotherapy experts describes immunotherapy response assessment 
for neuro-oncology (iRANO) criteria that are based on guidance for determination of tumor 
progression outlined by the immune-related response criteria (irRC) and the response assessment 
in neuro-oncology (RANO) working group. Among patients who demonstrate imaging findings 
meeting RANO criteria for progressive disease (PD) within six months of initiating 
immunotherapy including the development of new lesions, confirmation of radiographic 
progression on follow-up imaging is recommended provided that the patient is not significantly 
worse clinically. The proposed criteria also include guidelines for use of corticosteroids.  The role 
of advanced imaging techniques and measurement of clinical benefit endpoints including 
neurologic and immunologic functions are reviewed. The iRANO guidelines put forth herein will 
evolve successively to improve their utility as further experience from immunotherapy trials in 
neuro-oncology accumulates. 
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Introduction 
Immunotherapy for cancer has made exciting recent progress. The United States Food and Drug 
Administration (FDA) approved the first vaccine against non-viral cancers (sipuleucel-T)1 and 
blocking monoclonal antibodies (mAb) to the immune checkpoint molecules cytotoxic T 
lymphocyte-4 (CTLA-4; ipilimumab) and programmed death 1 (PD-1; pembroluzimab and 
nivolumab) for metastatic melanoma as well as non-small cell lung cancer (NSCLC).2-5   
Chimeric antigen receptor (CAR) engineered autologous T cells have induced durable remissions 
among leukemia patients refractory to conventional therapies including bone marrow 
transplantation.6,7 For patients with primary and metastatic neuro-oncology malignancies, clinical 
trials evaluating a variety of immunotherapeutic approaches are underway, and promising 
preliminary results are emerging.8-10 
 
Ongoing Evolution of Response Assessment in Neuro-Oncology 
Traditional imaging response assessment tools, including World Health Organization (WHO)11, 
Response Evaluation in Solid Tumors (RECIST)12, and Macdonald criteria13, originated in the 
cytotoxic therapy era where radiographic findings directly reflected anti-tumor effect. As 
oncology treatments have expanded beyond cytotoxic therapy, the impact of therapeutics on 
tumor imaging findings has become less straightforward. For neuro-oncology, pseudoprogression 
following radiotherapy and temozolomide chemotherapy (TMZ/RT→TMZ)14, and 
pseudoresponse following anti-angiogenic agents15, highlight challenges with interpreting 
imaging changes in the modern era.  The response assessment in neuro-oncology (RANO) 
criteria16 were proposed in 2010 to better assess evolving complexities of imaging assessment for 
malignant glioma patients. Subsequently, variations of RANO were refined for patients with low-
grade glioma17 and brain metastases.18 
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A key cornerstone of RANO is guidance for the phenomenon of pseudoprogression which occurs 
in approximately 10-20% of newly diagnosed glioblastoma patients following 
TMZ/RT→TMZ.14,19-21 The precise mechanism of pseudoprogression remains poorly understood, 
but most cases peak within three months of completing chemoradiation, although longer time 
courses have been reported.19 Thereafter, radiographic changes may stabilize and ultimately 
improve. RANO guidelines have been widely adopted in daily practice and clinical research. 
Specifically, RANO defines that progressive disease (PD) should be diagnosed radiographically 
no sooner than three months following completion of concomitant TMZ/RT, unless there is: 1) 
new enhancement outside the main radiation field or; 2) pathologic confirmation of unequivocal 
tumor progression. Furthermore, RANO permits patients with progressive radiographic findings 
of unclear etiology to continue current therapy pending follow-up imaging.  
Important issues regarding progressive imaging findings among neuro-oncology patients treated 
with immunotherapy suggest that further adaptation of RANO is warranted. First, the mechanism 
underlying pseudoprogression following immunotherapy is likely distinct from that associated 
with TMZ/RT→TMZ, with important differences in kinetics, frequency, and overall impact for 
patients. For example, although the temporal window for TMZ/RT→TMZ pseudoprogression 
generally peaks within three months, the time frame for immunotherapy-associated 
pseudoprogression remains to be defined and may differ by class of immunotherapeutic. Second, 
RANO does not permit treatment continuation beyond actual tumor progression because 
subsequent therapeutic benefit supporting this practice has not been documented for oncology 
treatments other than immunotherapies.  Third, appearance of a new lesion outside the main 
radiation field automatically defines PD in the RANO criteria. Finally, RANO does not require a 
repeat scan to confirm PD.  
 
Challenges Interpreting Worsened Radiographic Findings Following Immunotherapy 
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The interpretation of decreased size of an enhancing lesion is straightforward as such changes 
indicate a true anti-tumor effect because immunotherapeutics are not associated with 
pseudoresponse. In contrast, correct interpretation of progressive imaging findings following 
administration of immunotherapeutics is essential since early progressive radiographic changes 
do not always preclude subsequent therapeutic benefit.22-32 There are two main explanations for a 
possible disconnect between worsened early imaging findings and subsequent therapeutic benefit. 
First, effective immune responses may require time to evolve, and early imaging may show true 
PD, including the development of new lesions. Nonetheless, once induced, an effective anti-
tumor immune response may subsequently lead to clinical benefit. Second, because the mode of 
action may involve an inflammatory response in areas of macroscopic and microscopic 
infiltrative tumor, localized inflammatory responses can mimic radiologic features of tumor 
progression with increased enhancement and edema.33 
In an evaluation of 487 advanced melanoma patients treated with ipilimumab in three phase II 
studies, four patterns of radiographic response were observed.22 Two of these response patterns 
were captured by conventional WHO or RECIST criteria including: a) radiologic response in 
baseline lesions with no new lesions; and b) stable disease, which was followed by slow 
progressive decrease in tumor burden among some patients. Two other previously unrecognized 
patterns of response were not captured by conventional response assessment criteria. In some 
patients, an increase in size of existing lesions was followed by radiographic response or stable 
disease without the addition of further therapy other than ipilimumab. Among other patients, new 
lesions were noted early on, but subsequent response or stable disease was later achieved without 
alternative therapeutic intervention. Additional recent examples also highlight the potential for 
early imaging worsening to be misleading in patients undergoing immunotherapy. First, spider 
plots evaluating percent change in target lesion size from baseline over time for individual 
patients treated with anti-PD-1/PD-L1 therapy reveal enlargement of initial tumor or even new 
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lesions in some melanoma patients prior to eventual decrease in tumor size.26,28,31 Second, in an 
evaluation of 227 patients treated with ipilimumab, 22 patients (9·7%) who met WHO imaging 
criteria for PD subsequently demonstrated clinical benefit including five patients who ultimately 
achieved PR, and 17 with SD.22 In a phase II study of tremelimumab, another anti-CTLA-4 MAb, 
eight patients demonstrated a PR of target lesions by RECIST criteria concurrent with new 
lesions in six patients and progression of non-target lesions in two others.34 Of note, overall 
survival of these eight patients ranged from 21 to 39 months, whereas the median survival for all 
enrolled patients was 10·0 months. These examples underscore a potential disparity between 
early worsening on imaging assessment and ultimate clinical benefit including improved survival 
among patients treated with immunotherapy. 
The frequency of ultimate clinical benefit following early progressive imaging findings among 
neuro-oncology patients undergoing immunotherapy approaches is unknown.  Preliminary results 
of recently initiated clinical trials evaluating immune checkpoint blocking antibodies among 
recurrent glioblastoma patients and vaccines in WHO grade II low-grade glioma patients 
demonstrate that early progressive radiographic changes or appearance of new enhancing lesions 
may subsequently stabilize or disappear, respectively (Figure 1) .  
 
New lesions 
Appearance of new lesions is a criterion that defines progression of disease by RANO as well as 
Macdonald criteria. However, transient appearance of new enhancing lesions at either local or 
distant sites may occur among neuro-oncologic patients receiving immunotherapies (Figure 
1B).25,36 For cases of pseudoprogression, histopathology typically reveals remarkable immune cell 
infiltration, such as CD8+ T lymphocytes, but not mitotically active tumor cells.25 In such 
situations, careful radiologic and clinical assessments are warranted. In some cases, such new 
enhancing lesions may reflect immune responses directed against infiltrative brain tumor cells.  
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Confirmation of Radiographic Progression to Define Progressive Disease 
The immune-related response criteria (irRC) were issued to aid the interpretation of imaging 
changes among oncology patients undergoing immunotherapy.22,24,37 Their intent was to raise 
awareness that traditional imaging criteria to define PD may be less reliable and could lead to 
premature discontinuation of potentially beneficial therapy. A key component is the concept of 
confirmation of radiographic progression. irRC guidelines state that early increases in lesion size 
or new lesions do not define PD unless further progressive changes are confirmed upon follow-up 
imaging, provided that patients are not experiencing clinical decline.  Confirmation to define PD 
is an important, novel aspect of irRC, although the converse, requirement of follow-up imaging to 
confirm a radiographic response, has been an accepted component of most response assessment 
metrics including RANO. Particularly for indications such as glioblastoma, where effective 
therapeutic interventions are limited and durable responses are elusive, continuation of 
immunotherapies beyond initial progression may lessen the likelihood of prematurely 
discontinuing potentially effective therapy.2,22,24 
 
When Is Confirmation of Radiographic Progression Appropriate? 
A critical issue is to identify patients who develop early progressive imaging findings, but still 
will derive therapeutic benefit from those truly resistant and unlikely to benefit. According to 
most response assessment criteria, including RANO, patients with significant neurologic decline, 
regardless of imaging findings, are deemed to have PD, providing their decline is not attributable 
to co-morbid events such as seizures or changes in medication, notably decreased corticosteroid 
dosing. For such patients, radiographic confirmation of PD is neither necessary nor appropriate 
and their date of PD is the date they developed significant neurologic decline attributable to 
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underlying tumor. Future studies need to define the time window for patients without neurologic 
decline where early progressive imaging findings do not preclude subsequent clinical benefit. 
Experience among solid tumor patients treated with immune checkpoint blockade reveals that 
most patients who ultimately benefit demonstrate stable or improved radiographic findings within 
six months of initiating therapy, including those who exhibit early progressive radiographic 
findings.2,26,28,31 The kinetics of either pseudoprogression or delayed response following various 
types of immunotherapy among neuro-oncology patients require prospective evaluation. 
Nonetheless, anecdotal reports of glioma patients treated with tumor vaccination therapy have 
described pseudoprogressive radiographic findings that also typically manifest within six months 
of treatment initiation.25,36,38 
Conversely, there is no evidence that patients develop delayed clinical benefit or radiographic 
response if they develop progressive radiographic findings more than six months after initiating 
immunotherapy. In order to determine whether a six month window to recommend confirmation 
of radiographic progression is appropriate, the iRANO working committee advocates that the 
timeframe of pseudoprogression be prospectively evaluated in future immunotherapy trials. 
 
Three Months Period to Confirm Radiographic Progression 
Another critical unanswered question regarding the significance of early progressive imaging 
findings is how long such changes can evolve before clinicians can confidently conclude that they 
indicate PD. Is there a duration of time in which imaging findings may continue to worsen, but a 
given patient may still ultimately derive clinical benefit? Alternatively, how long should 
progressive imaging findings after initiation of immunotherapy be followed in order to 
confidently conclude that ultimate clinical benefit is unlikely?  
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The irRC guidelines recommend confirmation of progression with follow-up imaging at least four 
weeks from the initial scan documenting PD.22 Yet, four weeks may be too early to accurately 
ascertain the etiology of early progressive imaging changes and conclude that eventual clinical 
benefit is unlikely. In fact, spider-plots describing changes in tumor volume over time for solid 
tumor patients undergoing immune checkpoint blockade demonstrate that early progressive 
radiographic findings typically stabilize or improve within three months for the majority of 
patients who ultimately derive clinical benefit.26,28,31 Similarly, a three month window has been 
defined by RANO to determine the etiology of progressive imaging changes among malignant 
glioma patients following TMZ/RT→TMZ.14,39 
Based on these observations, the iRANO working committee recommends that among patients 
with early progressive imaging findings including the development of new lesions who are not 
experiencing significant neurologic decline, confirmation of radiographic progression via follow-
up imaging should be sought no sooner than three months after initial radiographic evidence of 
PD is detected, to decrease the likelihood of prematurely declaring PD in patients with 
pseudoprogression or delayed response. Imaging within the three months follow-up period can be 
performed as medically appropriate at the discretion of the treating clinician. 
Among such patients, those with confirmation of further radiographic progression based on 
comparison to the scan which first revealed evidence of progression, or who exhibit significant 
clinical decline at any time, should be classified as progressive with the date of disease 
progression back-dated to the first date that the patient met criteria for radiographic progression. 
Such patients should be discontinued from their current immunotherapy regimen.  
In the event that follow-up imaging does not confirm further progression compared to the scan 
which first revealed initial progressive changes, but instead reveals stabilization or reduction in 
tumor burden, in the absence of increased corticosteroid dosing, treatment should be continued or 
resumed.  
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Figure 2 provides an algorithm summarizing guidance on follow-up imaging following initial 
progressive changes. 
 
Tissue Acquisition to Aid Response Assessment 
 In uncertain cases in which acquisition of tumor histopathology via biopsy or resection is 
considered feasible, pathological assessment may be considered to clarify the etiology of 
progressive imaging findings. If pathology confirms a predominance of recurrent tumor, the 
etiology should be considered to be true progression. For cases where no evidence of viable 
tumor is detected, or where a prominence of gliosis/inflammation with limited viable tumor is 
observed, the etiology should be considered consistent with treatment effect, and such patients 
should be classified as stable and allowed to continue therapy.  
Although considered a “gold standard”, interpretation of tissue may be challenging. Biopsies 
typically acquire very small tissue aliquots and thus may be subject to “sampling artifact”. In 
addition, many specimens will reveal mixed findings indicating the presence of viable tumor as 
well as treatment effect (inflammation, necrosis, etc.) and guidance on appropriate interpretation 
of such specimens is currently lacking. It will be critically important that neuropathologists and 
neuro-oncologists prospectively prioritize careful evaluation of histopathologic samples obtained 
from patients undergoing immunotherapy to better understand the significance of various patterns 
of mixed tissue findings.  
 
Immunotherapy Continuation Pending Confirmation of Progression 
Currently, it is not established whether continued immunotherapy following initial progression on 
imaging studies would provide treatment efficacy or harm to patients and further careful study of 
this important question is warranted. A decision whether a patient should continue 
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immunotherapy pending confirmation of radiographic progression should be determined based on 
perceived benefits and risks. Continuation of immunotherapy may be considered pending follow-
up imaging as long as patients are deriving apparent clinical benefit with minimal and acceptable 
toxicity. In contrast, clinicians may consider interrupting immunotherapy for patients who require 
a significant increase in corticosteroids (i.e. > 4 mg of dexamethasone or equivalent per day) for 
evolving symptoms associated with cerebral edema or who are experiencing more than mild 
treatment-related toxicity such as immune related adverse events grade ≥ 2.  
Although somewhat arbitrarily set and not based on definitive data, these guidelines are included 
to limit the likelihood of progressive immunotherapy-induced inflammatory changes leading to 
significant deficits in otherwise stable or asymptomatic patients. In such patients, an interruption 
of immunotherapy dosing may be considered pending follow-up imaging. Further, one may opt to 
discontinue or interrupt immunotherapy at any time if this seems to be in the best medical interest 
of the patient. As general guidance, resumption of immunotherapy may be considered when 
systemic dexamethasone is decreased to ≤ 4 mg/day and enhancing tumor burden is classified as 
SD, PR, or CR on follow-up scan, or when relevant treatment-related toxicity has resolved to 
grade ≤ 1 or pre-treatment baseline.  
 
Immunotherapy Response Assessment in Neuro-Oncology (iRANO) Criteria 
The immunotherapy response assessment in neuro-oncology (iRANO) guidelines incorporate 
criteria previously defined by the RANO working committee to define CR, PR, minor response, 
SD, PD, and non-evaluable, for patients with malignant glioma,16 low-grade glioma40 and brain 
metastases.18 The key component of iRANO is specific additional guidance for the determination 
of PD among neuro-oncology patients undergoing immunotherapy (Table 1; Figure 2). 
Specifically, iRANO advocates the confirmation of radiographic progression in appropriate 
patients defined by clinical status and time from initiation of immunotherapy.  
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Among patients who demonstrate imaging findings that meet RANO criteria for PD16-18 within 
six months of initiating immunotherapy including the development of new lesions, it may be 
appropriate to consider obtaining confirmation of radiographic progression on follow-up imaging 
before defining the patient a treatment failure provided that the patient is not experiencing new or 
worsened significant neurologic deficits. Such patients may be allowed a window of three months 
prior to confirming progression using the scan which first revealed initial progressive changes as 
the new reference scan for comparison with subsequent imaging studies. If RANO criteria for PD 
are met on the follow up scan at three months later, treatment failure should be assumed, and the 
date of PD should be back-dated to the initial date when it was identified (Table 1). Patients who 
develop significant new or worsened neurologic deficits not due to co-morbid event or change in 
co-administered medication at any time within the three months follow-up window should be 
designated as a treatment failure and should discontinue immunotherapy. For these patients, the 
date of actual tumor progression should also be back-dated to the date radiographic PD was 
initially identified.  
If radiographic findings at the three month follow-up meet criteria for SD, PR, or CR according to 
RANO criteria16-18 compared to the original scan meeting criteria for progression, and there are 
no new or worsened neurologic deficits, such patients should be considered as deriving clinical 
benefit from therapy and allowed to continue treatment. 
Patients who develop worsening radiographic findings compared to the pre-treatment baseline 
scan more than six months from immunotherapy initiation are expected to have a low likelihood 
of ultimately deriving clinical benefit and should be considered a treatment failure with a 
recommendation to discontinue their current therapy. 
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In summary, we have integrated guidance from the irRC regarding interpretation of progressive 
imaging findings with existing RANO criteria to form the iRANO guidelines. Comparison of the 
key features associated with RANO, irRC and iRANO are summarized in Table 2.  
Although application of immunotherapies for neuro-oncology patients is in early stages and much 
remains to be learned, iRANO provides guidelines that can be applied to provide consistent 
metrics in clinical trials as well daily practice. In particular, these guidelines shall raise awareness 
of the possibility of potentially misleading early progressive radiographic changes following 
initiation of immunotherapy, as well as guidance for responding to these changes in order to 
decrease the likelihood of inappropriate premature therapy discontinuation. It is the expectation 
of the multinational, multidisciplinary co-authorship of this manuscript that the iRANO 
guidelines put forth herein will be amended successively to improve their utility as further 
experience and systematic data from ongoing immunotherapy trials in neuro-oncology 
accumulate. 
 
Corticosteroids  
Patients with brain tumors frequently develop peritumoral edema requiring treatment with 
corticosteroids. Dexamethasone is the most commonly used corticosteroid.41,42 In addition to 
systemic side effects, dexamethasone can have profound effects on contrast enhancement for 
neuroimaging studies and on the immune system, especially T cells.43 In preclinical studies, 
administration of dexamethasone to rats bearing intracranial C6 glioblastomas dose-dependently 
decreased intratumoral infiltration by lymphocytes and microglial cells44, and limited cytokine-
mediated antitumor effects and survival of rats bearing 9L gliomas.45 
Several clinical studies have demonstrated that dexamethasone can inhibit maturation of dendritic 
cells and consequently their potential for antigen presentation.46,47 In cancer patients receiving 
immunotherapy, dexamethasone can also impair natural killer (NK) cell activity.48 In 
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glioblastoma patients, treatment with dexamethasone favors the emergence of a population of 
CD14+ HLA.DR low/neg monocytes that inhibit T cell proliferation.49 
Most of the data on the impact of corticosteroids on immune system activity derive from 
evaluation of relatively high dosing schedules. In contrast, minimal data exists on the effects of 
differential doses50,51 while the long-term effects of low/moderate dexamethasone doses on 
immune cell function remain unclear. Nonetheless, given its potential negative effects on 
dendritic cell, T-cell and NK cell function, dexamethasone doses and duration of therapy should 
be limited to the minimum amount required to control neurological symptoms.  
As a general guideline, patients enrolling in immunotherapy trials should be as little 
dexamethasone as possible prior to treatment initiation. During the course of treatment, if 
pseudoprogression occurs, higher doses of corticosteroids may be necessary to control symptoms. 
While this may potentially reduce immunotherapy efficacy, available data at present are 
inconclusive. In a trial of ipilimumab for brain metastases from melanoma, patients who required 
corticosteroids during study therapy had a worse outcome.52 Although this could be due to a 
negative effect of corticosteroids on immune function, it is also possible that the group requiring 
corticosteroids had larger tumors and worse prognostic factors.  
 
Of note, patients who require increased corticosteroids within two weeks of MRI assessment 
relative to the dose taken at the time of the prior assessment, cannot be classified as CR, PR, or 
SD and should be classified as non-evaluable at that time point. Conversely, patients who 
decrease corticosteroids within two weeks of MRI assessment, relative to the dose taken at the 
time of the prior assessment, cannot be classified as PD and should be classified as non-
evaluable. 
 
Conclusion 
[15] 
 
We propose updated response assessment criteria for the evaluation of neuro-oncology patients 
undergoing immunotherapy. These recommendations integrate the framework of response 
assessment established by the RANO working group for malignant glioma,16  low-grade glioma40, 
and brain metastases18 with guidance for confirmation of progression as originally advocated by 
the irRC criteria to guide clinical decision making. The iRANO guidelines specifically address 
interpretation of initial progressive imaging findings in the context of neuro-oncology patients 
with a goal of decreasing the likelihood of premature discontinuation of potentially beneficial 
therapies while ensuring maximum patient safety. The iRANO guidelines will inevitably require 
future amendment including possible incorporation of advanced imaging techniques, once 
sufficient experience and expertise are acquired for each of the major classes of immune-based 
therapies among neuro-oncology patients. Prospective evaluation of the iRANO criteria in brain 
tumor immunotherapy trials for neuro-oncology patients will be required to confirm their ultimate 
clinical utility.  
 
Search strategy and selection criteria 
A systematic search of PubMed was undertaken between January, 1980, and March, 2015, with 
(combinations of) the key words: “glioma”, “glioblastoma”, “immunotherapy”, “imaging”, 
“corticosteroid”, and “response criteria”. Articles were also identified through searches of the 
authors’ own files. Only papers published in English were considered. The final reference list was 
generated on the basis of originality and relevance to the broad scope of this Review. 
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FIGURE LEGENDS 
Figure 1. (A) Axial T1 contrast Gd-enhanced and FLAIR images obtained prior to, and 7 and 13 
weeks after initiation of CTLA-4 immune checkpoint blockade.35 (B) Axial T2 FLAIR and T1 
Gd-enhanced images obtained post 2nd (left), at 11 days post 3rd (middle) and 19 days post 3rd 
(right) vaccinations (NCT01678352) in a patient with recurrent WHO grade II oliodendroglioma. 
Figure 2. Algorithm for evaluation of progressive imaging findings among neuro-oncology 
patients undergoing immune-based therapies.  
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Table 1 
Complete Response 
Partial Response 
Stable Disease 
Minor Response 
Progressive Disease 
iRANO 
RANO Criteria  
Low-Grade Glioma17 Malignant Glioma16 Brain Metastases18 
-Disappearance of all enhancing  
disease for ≥ 4 weeks AND 
- No new lesions AND  
- Stable/improved T2/FLAIR AND  
- No more than physiologic steroids AND  
- Stable/improved clinically 
- ≥ 25% ↑ sum of biperpendicular  
diameters of enhancing disease OR  
- New lesions OR  
- Significant worsened T2/FLAIR OR  
- Significant clinical decline 
- Non-applicable 
- Does not qualify for CR, PR, PD AND  
- No new lesions AND  
- Stable/improved T2/FLAIR AND  
- Stable/improved steroids AND 
- Stable/improved clinically 
- ≥ 50% ↓ sum of biperpendicular diameters 
of enhancing disease for ≥ 4 weeks AND  
-  No new lesions AND  
- Stable/improved T2/FLAIR AND  
- Stable/improved steroids AND 
- Stable/improved clinically 
-Disappearance of all enhancing and T2/FLAIR 
disease for ≥ 4 weeks AND 
- No new lesions AND  
- No more than physiologic steroids AND  
- Stable/improved clinically 
- ≥ 50% ↓ sum of biperpendicular diameters 
of T2/FLAIR disease for ≥ 4 weeks AND  
- No new lesions AND 
- Stable/improved steroids AND  
- Stable/improved clinically 
- 25-49% ↓ sum of biperpendicular  
diameters of T2/FLAIR disease for ≥ 4 weeks AND  
- No new lesions AND  
- Stable/improved clinically 
- Does not qualify for CR, PR, PD AND  
- No new lesions AND  
- Stable/improved T2/FLAIR AND  
- Stable/improved steroids AND 
- Stable/improved clinically 
- ≥ 25% ↑ sum of biperpendicular  
diameters of T2/FLAIR disease OR  
- New lesions OR  
- Significant clinical decline 
-Disappearance of all enhancing target and  
non-target lesions for ≥ 4 weeks AND 
- No new lesions AND  
- No steroids AND  
- Stable/improved clinically 
- ≥ 30% ↓ sum of longest diameters 
of target lesions for ≥ 4 weeks AND  
- No new lesions AND 
- Stable/improved steroids AND  
- Stable/improved clinically 
Not applicable 
- Does not qualify for CR, PR, PD 
- ≥ 20% ↑ sum of longest 
diameters of target lesions OR  
-Unequivocal progression of enhancing 
non-target lesions OR 
- New lesions OR  
- Significant clinical decline 
• Confirmation of progression on follow-up imaging 3 months after initial radiographic progression if: 
1. No new or significantly worsened neurologic deficits not due to co-morbid event or concurrent medication AND 
2. ≤ 6 months from initiation of immunotherapy 
 If follow-up imaging confirms progression, the date of actual progression should be back-dated to the date of initial  radiographic progression 
• Appearance of new lesions solely does not define progressive disease≤ 6 months from initiation of immunotherapy. The lesions are added to the 
total lesion areas for follow-up assessments. 
Table 2. Key Considerations: RANO, irRC and iRANO 
 RANO irRC iRANO 
(if ≤ 6 months 
after start of 
immunotherapy) 
iRANO 
(if > 6 months 
after start of 
immunotherapy) 
Is a repeat scan required to 
confirm radiographic PD for 
patients without significant 
clinical decline? 
No Yes Yes No 
Minimal time interval for 
confirmation of progression for 
patients without significant 
clinical decline? 
Not 
applicable 
≥ 4 
weeks 
≥3 months Not applicable 
Is further immunotherapy 
treatment allowed after initial 
radiographic PD (if clinically 
stable) pending progression 
confirmation 
Not 
applicable 
Yes Yes Not applicable 
Does a new lesion define PD? Yes No No Yes 
 
 
